Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + SHR-A1811 as Neoadjuvant Therapy for TNBC
NCT07466303Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Mar 2026
- Primary completion
- Feb 2028
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, trastuzumab rezetecan in triple-negative breast cancer (TNBC), sponsored by Xijing Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
serplulimabtrastuzumab rezetecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07466303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466303.